Timberlyne Therapeutics: Funding, Investors & Team (Sep 2026)
Timberlyne Therapeutics is a biopharmaceutical company in the clinical stage that specializes in creating and selling groundbreaking medications for autoimmune diseases. The company uses its team's expertise in drug development to acquire high-quality assets that target promising areas and apply them to medical conditions with significant gaps in treatment options.
Timberlyne Therapeutics has raised $180M across 1 funding round on record, the most recent a Series A of $180M announced in Jan 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Timberlyne Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2025.
Timberlyne Therapeutics Funding Rounds
Timberlyne Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Timberlyne Therapeutics Funding Compared to Other Biotechnology Startups
Timberlyne Therapeutics' latest round of $180M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Timberlyne Therapeutics in Biotechnology and San Diego
Companies Similar to Timberlyne Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Timberlyne Therapeutics Funding FAQs
What does Timberlyne Therapeutics do?
Timberlyne Therapeutics is a biopharmaceutical company in the clinical stage that specializes in creating and selling groundbreaking medications for autoimmune diseases. The company uses its team's expertise in drug development to acquire high-quality assets that target promising areas and apply them to medical conditions with significant gaps in treatment options.
How much funding has Timberlyne Therapeutics raised?
Timberlyne Therapeutics has raised $180M across 1 round on record. The most recent is a Series A of $180M announced in Jan 2025.
When did Timberlyne Therapeutics last raise funding?
Timberlyne Therapeutics' most recent funding round on record is a Series A of $180M, announced in Jan 2025.
Who founded Timberlyne Therapeutics?
FundedIQ lists Christian Fougner (Founder) at Timberlyne Therapeutics.
Where is Timberlyne Therapeutics headquartered?
Timberlyne Therapeutics is based in San Diego, California, United States.
How many employees does Timberlyne Therapeutics have?
Timberlyne Therapeutics is in the 11-50 employee band.
How does Timberlyne Therapeutics' funding compare to other Biotechnology startups?
Timberlyne Therapeutics' latest round of $180M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Timberlyne Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Timberlyne Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.